KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.
Key Financial Performance
Revenue (Q4 2025) $10.9 million, a 23% year-over-year growth. This marks the third consecutive quarter of greater than 20% revenue growth. Growth driven by Domestic Core (18% YoY) and International Core (71% YoY) segments.
Revenue (Full Year 2025) $41.1 million, a 22% increase over the prior year. Growth driven by Domestic Core (11% YoY) and International Core (80% YoY). Adjusted for distributor sales dynamics, underlying growth was 14% (Domestic) and 73% (International).
Gross Margin (Q4 2025) Slight 30 basis point reduction compared to Q4 2024, driven by higher material costs and tariffs, partially offset by a stronger customer mix in the U.S.
Gross Margin (Full Year 2025) 62.3%, a decrease due to higher packaging material costs, tariff-related charges, and geographic sales mix from growing international business.
Cash Position (End of 2025) $8.9 million, with full-year cash usage of $700,000. Achieved positive cash flow from operations in Q3 and Q4 2025.
Adjusted EBITDA (Full Year 2025) $600,000, a 124% improvement compared to the prior year, marking three consecutive quarters of positive adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RYSTIGGO 510(k) clearance: Received clearance for RYSTIGGO, marking the ninth drug cleared on the Freedom Infusion System and the second non-IG clearance. This enables entry into the infusion clinic channel.
New pharma collaborations: Announced two new collaborations for a Phase III nephrology molecule and a Phase I multi-indication drug, expanding the development pipeline.
Next-generation pump: FREEDOM60 next-generation pump expected to have 510(k) and MDR submissions in 2026.
International Core growth: Achieved 80% growth in the international market, increasing European market share from 10% to 20%.
Prefilled syringe conversions: Received EU MDR certification for FREEDOM60 with prefilled syringe compatibility, driving market share growth in Europe.
Revenue growth: Achieved $41.1 million in revenue for 2025, a 22% increase year-over-year.
Cash flow: Ended 2025 with $8.9 million in cash and achieved positive cash flow from operations.
Leadership transition: CEO Linda Tharby announced retirement effective June 30, 2026, with Adam Kalbermatten succeeding her.
Market expansion strategy: Focused on expanding subcutaneous drug delivery market, targeting 95 large-volume drugs in development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CEO Transition: The retirement of the current CEO, Linda Tharby, and the transition to a new CEO, Adam Kalbermatten, could pose strategic execution risks during the leadership change. Ensuring a smooth transition is critical to maintaining momentum and achieving strategic goals.
Geopolitical Risks: The company has incorporated geopolitical risks, particularly recent events in the Middle East, into its 2026 revenue guidance. These risks could impact international operations and revenue growth.
Supply Chain and Material Costs: Higher material costs and tariffs have impacted gross margins, and continued external cost pressures could further affect profitability.
Regulatory and Market Entry Risks: The company is pursuing multiple regulatory clearances (e.g., 510(k) and MDR submissions) for new products and market entries. Delays or failures in obtaining these clearances could hinder growth and market expansion.
International Expansion Challenges: While international markets, particularly Europe, present significant growth opportunities, the company faces challenges in scaling operations, managing geographic sales mix, and navigating regulatory environments.
Pipeline and Collaboration Risks: The company is heavily reliant on its pipeline of new drug collaborations and regulatory approvals. Delays or failures in these collaborations could impact future revenue streams.
Economic and Market Conditions: The company operates in a market with projected growth rates of 8%-10%, but economic uncertainties and market dynamics could affect demand for its products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: KORU Medical Systems projects revenue of $47.5 million to $50 million for 2026, representing growth of 15% to 22%.
Profitability and Cash Flow: The company expects to achieve positive adjusted EBITDA and positive cash flow for the full year 2026.
Gross Margin: Gross margins are projected to be in the range of 61% to 63% for 2026.
Revenue Drivers: Key revenue drivers include U.S. and international share gains in SCIg, NRE revenue from at least 4 new collaborations, and incremental revenue from recent or pending 510(k) clearances.
Market Trends: The global SCIg market is expected to grow 8% to 10% annually over the next five years, with KORU aiming to outperform this growth rate.
New Product Launches: The FREEDOM60 next-generation pump is expected to have 510(k) and MDR submissions in 2026, with the Phase II Flow Controller submission projected for late 2026 or early 2027.
International Expansion: KORU plans to expand its presence in the European market, leveraging MDR clearance for the FREEDOM60 system with prefilled syringe compatibility.
Pipeline Development: The company has 9 active drug opportunities in its pipeline, with 2 new collaborations signed in Q4 2025. These include a Phase III nephrology drug and a Phase I multi-indication drug, representing a combined commercial opportunity of approximately 3 million annual infusions.
Non-IG Drug Opportunities: KORU anticipates commercial opportunities in 2026 for RYSTIGGO and Phesgo, marking its entry into the infusion clinic and oncology markets.
Long-Term Goals: The company aims to achieve $100 million in revenue, gross margins above 65%, and an EBITDA margin of 20% or greater in the long term.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What does the FREEDOM60 product do for the market, and how much of the market might it open up?
A:The FREEDOM60 product targets a $50 million total addressable market in Europe. The company successfully increased its share from 10% to 20% in 2025, with potential to reach closer to its 60% U.S. share. The opportunity is driven by prefill conversions in major European markets, with plans to expand to new markets in 2026.
Q:What is the cadence of entering the 5 geographies mentioned?
A:The 5 geographies are existing markets with low penetration. The company plans to grow these markets significantly through prefill launches, with 1 to 2 new markets being added every quarter in 2026.
Q:What is the status of the FREEDOM60 and Edge pumps?
A:Both the FREEDOM60 and Edge pumps are approved. The FREEDOM60 required slight modifications and an updated IFU, which was approved in Q4 2026. The new product is now being distributed, and the FREEDOM360 pump, compatible with all prefills, is expected by the end of 2026.
Q:What is the composition of the guidance for 2026, including U.S. and OUS contributions?
A:The company expects strong momentum in Q1 2026, with international growth driven by prefill launches and a step-up in the back half of the year. U.S. growth is expected to be steady, with contributions from new drug approvals and consistent revenue trajectory in the PST segment.
Q:What is driving the 18% domestic growth, and what is the opportunity for further share gains in 2026?
A:The 18% growth is driven by new account gains and the return of a distributor from international to the U.S. market. The company expects continued growth in the SCIg market and from new drug approvals throughout 2026.
Q:What is the impact of novel therapies and operating leverage expectations for 2026?
A:Novel therapies, now called the PSD business, are milestone-based and expected to remain consistent with historical levels. Two new deals were signed, representing approximately 3 million annual infusions. Operating leverage is expected to improve, with positive adjusted EBITDA and cash flow for the full year.
Q:What is the go-to-market model for RYSTIGGO in infusion clinics, and how does it position the company for oncology opportunities?
A:RYSTIGGO is expected to grow from 20,000 to 100,000 infusions in the U.S. over 5 years. The entry into infusion clinics, which overlaps with oncology infusion centers, provides a head start for future oncology opportunities. The company collaborates with UCB and sees significant growth potential in this channel.
Q:What are the factors influencing the guidance range for 2026?
A:The guidance range depends on the speed of prefill conversions, new drug traction, Middle East market timing, and oncology opportunities. Faster execution in these areas could push results to the high end of the range.
Q:What is the outlook for the Japan market in 2026?
A:Japan is seen as a $0.5 million to $1 million opportunity, transitioning from hospital to home use. Both pumps and consumables are approved, and growth is expected to align with the expansion of prefilled syringes.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the broader opportunity of new drugs in infusion clinics, stating they would refresh models as time goes on. Additionally, they did not provide detailed operating leverage figures for 2026, only indicating continued progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Commercial
Core SCIg
Domestic International
FREEDOM
IG infusion
III nephrology
Infusion system
International Core
Kalbermatten Chief
MDR certification
Phase drug
RYSTIGGO drug
SID
System
UCB
activity
administration
area
career
chapter
clearance RYSTIGGO
clinic channel
drug development
entry infusion
family
highlight
home
industry
infusion IG
molecule
opportunity infusion
pharma collaboration
reduction
role
shift
tech
transition
year SCIg
KRMD Transcript
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlighted strong growth in prefilled syringes, a strategic focus on expanding international markets, and a positive cash flow reinvestment plan. Although there were some delays and uncertainties, the company is mitigating these effectively. The Q&A section revealed optimism about future growth, particularly with new product launches and international expansion. Overall, the sentiment is positive, with potential for stock price appreciation given the strong business fundamentals and strategic initiatives.
KORU Medical Systems, Inc. (NASDAQ:KRMD) Q4 2024 Earnings Call Transcript
Positive3-13
The earnings call reveals strong financial performance with 23% Q4 revenue growth and improved gross margins. Guidance indicates continued growth, particularly in international markets, and cash flow positivity by 2025. However, management's lack of clarity on certain projections and potential supply chain cost impacts could temper enthusiasm. Overall, the positive financial metrics and optimistic guidance, especially in novel therapies and international growth, suggest a positive stock price movement.
KRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
